AMPH Q1 2021 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$103M+21.6% YoY

Gross Profit

$45M43.6% margin

Operating Income

$10M10.0% margin

Net Income

$5M4.9% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+7.4%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$15M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$646M

Total Liabilities

$195M

Stockholders' Equity

$406M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$85M	+21.6%
Gross Profit	$45M	$37M	+22.1%
Operating Income	$10M	$7M	+37.8%
Net Income	$5M	$4M	+27.7%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$5M100%

Geographic Segments

U

$99M99%

C

$1M1%